Brief: Relmada Therapeutics Initiates Phase 1 Dosing With REL-P11 For Metabolic Disease
14/11/2024 13:15
Nov 14 (Reuters) - Relmada Therapeutics Inc RLMD.O :
* RELMADA THERAPEUTICS INITIATES PHASE 1 DOSING WITH REL-P11
FOR
METABOLIC DISEASE
* RELMADA THERAPEUTICS INC - PHASE 2A PROOF-OF-CONCEPT STUDY
EXPECTED TO BEGIN IN H1 2025
Source text: ID:nGNX4sn4n2
Further company coverage: RLMD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million